BioCardia (NASDAQ:BCDA) Upgraded at Alliance Global Partners

BioCardia (NASDAQ:BCDA) was upgraded by investment analysts at Alliance Global Partners from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of BioCardia in a research note on Wednesday, December 18th.

BioCardia Price Performance

Shares of BioCardia stock opened at $2.47 on Thursday. BioCardia has a 1-year low of $1.63 and a 1-year high of $8.85. The stock has a market cap of $11.31 million, a P/E ratio of -0.59 and a beta of 1.26. The stock’s 50 day simple moving average is $2.20 and its 200-day simple moving average is $2.52.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.